The Cancer Genetics Program (CGP) is an interdisciplinary research group of 37 investigators from 13 departments and three different schools/colleges, Since the past funding cycle, tine research base of the Cancer Genetics Program has increased 180% from $3,866,370 to $10,978,820 total annual direct support, of which $1,132,859 is from the NCI. Over this last grant period, there were 472 publications of Cancer Genetics Program members, of which 8.4% are intra-programmatic and 31.9% are Inter-programmatic. The CGP pursues laboratory and translational research, emphasizing genetic and genomics approaches, with the overarching goal of advancing knowledge of the nature and role of mutations and gene expression changes In the development and altered phenotypic traits of cancer. Investigatory in the CGP are committed to the pursuit of research that will not only inform understanding of the origins and nature of cancer but that will also lead to novel diagnostic approaches for cancer and improved clinical management of cancer patients. Investigators in the Program collaborate with investigators in other University of Michigan Comprehensive Cancer Center (UMCCC) programs in the Basic Science, Clinical Science and Population Sciences Divisions, including Cancer Cell Biology, Radiation Sciences, Experimental Therapeutics, Breast Oncology, GI Oncology, Prostate Oncology, and Biomedical Prevention. The CGP has four major research themes: I) Defining oncogene and tumor suppressor gene network defects and gene expression signatures in cancers of various types. II) Characterization of mechanisms of gene regulation by transcription factor complexes and chromatin modification factors in cancer cells. III) Elucidation of genetic and epigenetic mechanisms contributing to genomic instability in cancer. IV) Development of genetically engineered mouse models for investigating the role of recurrent gene defects in cancer pathogenesis.

Public Health Relevance

Cancer Genetics Program members conduct research to identify the many types of genetic and epigenetic alterations that occur in various human cancers and aim to utilize the knowledge gained from such studies to develop more effective ways to detect, prognosticate, and treat cancer. Members also develop genetically engineered mouse models of cancer and cell-based systems to better understand the factors and mechanisms that influence cancer development, progression, and metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-26
Application #
8696601
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
26
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Skolarus, Ted A; Metreger, Tabitha; Hwang, Soohyun et al. (2017) Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials 18:181
Hertz, Daniel L; Speth, Kelly A; Kidwell, Kelley M et al. (2017) Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients. Breast Cancer Res Treat 165:659-668
Pinskey, Justine M; Franks, Nicole E; McMellen, Alexandra N et al. (2017) Neuropilin-1 promotes Hedgehog signaling through a novel cytoplasmic motif. J Biol Chem 292:15192-15204
Maj, Tomasz; Wang, Wei; Crespo, Joel et al. (2017) Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332-1341
Zhang, Jie; Feng, Shumei; Su, Wenmei et al. (2017) Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer. Sci Rep 7:42819
Mann, J E; Hoesli, R; Michmerhuizen, N L et al. (2017) Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC. J Cancer 8:332-344
Birkeland, Andrew C; Foltin, Susan K; Michmerhuizen, Nicole L et al. (2017) Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma. Oral Oncol 68:5-8
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Chen, Yan; Zhou, Quan; Li, Xue et al. (2017) Ultrasmall Paramagnetic Iron Oxide Nanoprobe Targeting Epidermal Growth Factor Receptor for In Vivo Magnetic Resonance Imaging of Hepatocellular Carcinoma. Bioconjug Chem 28:2794-2803

Showing the most recent 10 out of 1355 publications